Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewIEM 1754 dihydrobromide
Description: Voltage-dependent, open-channel AMPA blocker
Chemical Name: N-(Tricyclo[3.3.1.13,7]dec-1-ylmethyl)-1,5-pentanediamine dihydrobromide
Purity: ≥98% (HPLC)
Biological Activity for IEM 1754 dihydrobromide
IEM 1754 dihydrobromide is a voltage-dependent open-channel blocker of AMPA receptors. Selective between subtypes; blocks GluA2 subunit-lacking (Ca2+-permeable) receptors more potently than GluA2-containing receptors. Also potently blocks NMDA receptor channels. Less sensitive than IEM 1460 (Cat. No. 1460) at a holding potential between -40 and -80mV.
Technical Data for IEM 1754 dihydrobromide
| M. Wt | 412.25 |
| Formula | C16H30N2.2HBr |
| Storage | Store at RT |
| Purity | ≥98% (HPLC) |
| CAS Number | 162831-31-4 |
| PubChem ID | 9887867 |
| InChI Key | JMPHTNNJCZDROM-UHFFFAOYSA-N |
| Smiles | NCCCCCNCC1(CC3C2)CC(C3)CC2C1.Br.Br |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Product Datasheets for IEM 1754 dihydrobromide
References for IEM 1754 dihydrobromide
References are publications that support the biological activity of the product.
Magazanik et al (1997) Block of open channels of recombinant AMPA receptors and native AMPA/kainate receptors by adamantane derivatives. J.Physiol. 505 655 PMID: 9457643
Tikhonov et al (2000) Voltage-dependent block of native AMPA receptor channels by dicationic compounds. Br.J.Pharmacol. 129 265 PMID: 10694232
View Related Products by Target
View Related Products by Product Action
Keywords: IEM 1754 dihydrobromide, IEM 1754 dihydrobromide supplier, IEM1754, 2HBr, AMPA, receptor, blocker, blocks, AMPAR, voltage-dependent, Receptors, 4199, Tocris Bioscience
Citations for IEM 1754 dihydrobromide
Citations are publications that use Tocris products.
Currently there are no citations for IEM 1754 dihydrobromide.
Reviews for IEM 1754 dihydrobromide
There are currently no reviews for this product. Be the first to review IEM 1754 dihydrobromide and earn rewards!
Have you used IEM 1754 dihydrobromide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's Disease Poster
Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.